Klotho-derived peptide 1 ameliorates hepatic fibrosis induced by αKlotho deficiency and liver injury

International Journal of Biological Sciences 2026 Open access

Read full text
Authors: Huishi Tan, Wenshu Huang, Hanying Luo, Wenjian Min, Xiaoyao Zhang, Xiaoli Sun, Enqing Lin, Xue Hong, Peng Yang, Lili Zhou, Youhua Liu
DOI: 10.7150/ijbs.122107
Cited by: 2

Abstract

mice. In mouse model of carbon tetrachloride-induced hepatic fibrosis, KP1 exhibited preferential accumulation in injured liver after intravenous injection, disrupted TGF-β1/TβR2 interaction, inhibited HSCs activation, and ameliorated hepatic fibrosis. Similarly, KP1 also mitigated cholestatic fibrosis induced by bile duct ligation. Collectively, these studies establish KP1 as a novel, mechanism-driven therapeutic peptide that potently inhibits HSCs activation and liver fibrogenesis. Its liver-targeted delivery and efficacy across diverse fibrosis models underscore KP1 as a promising next-generation therapeutic remedy for fibrotic liver disease.

Fields of Study & Subjects

Liver physiology and pathology Parathyroid Disorders and Treatments Genetic and Kidney Cyst Diseases

Publication details

Journal / source
International Journal of Biological Sciences
Publisher
Ivyspring International Publisher
Volume
22
Issue
3
Pages
1425–1439
Publication date
8 January 2026
Language
EN